Pretax income is the income that a company earns before paying income taxes. Sagimet Biosciences's pretax income for the
three
months ended in Mar. 2024 was $-6.63 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-27.92 Mil.
Sagimet Biosciences's pretax margin was %.
During the past 5 years, Sagimet Biosciences's highest Pretax Margin was -1393.80%. The lowest was -1395.90%. And the median was -1393.80%.
Sagimet Biosciences Pre-Tax Income Historical Data
The historical data trend for Sagimet Biosciences's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sagimet Biosciences's Pre-Tax Income
For the Biotechnology subindustry, Sagimet Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Pre-Tax Income falls into.
Sagimet Biosciences Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Sagimet Biosciences's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (NAS:SGMT) Pre-Tax Income Explanation
Sagimet Biosciences's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 5 years, Sagimet Biosciences's highest Pretax Margin was -1393.80%. The lowest was -1395.90%. And the median was -1393.80%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Sagimet Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Sagimet Biosciences (Sagimet Biosciences) Business Description
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGMT has been successfully added to your 